CFM
AMRX icon

Catalyst Funds Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Catalyst Funds Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$293K Sell
16,900
-3,500
-17% -$48K 0.02% 501
2026
Q1 		$254K Buy
20,400
+3,500
+21% +$47K 0.04% 404
2025
Q4 		$213K Hold
16,900
– – 0.05% 282
2025
Q3 		$169K Sell
16,900
-21,800
-56% -$196K 0.03% 436
2025
Q2 		$313K Buy
+38,700
New +$292K 0.09% 265
2024
Q2 		– Sell
-10,400
Closed -$63K – 1166
2024
Q1 		$63K Buy
+10,400
New +$58.6K 0.02% 503

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Catalyst Funds Management's AMRX Position: Q2 2026 in Review

Catalyst Funds Management reduced its Amneal Pharmaceuticals (AMRX) stake by 17% in Q2 2026, selling an estimated $48K and leaving 16,900 shares worth $293K. The position accounts for 0.02% of the portfolio, ranked #501.

Catalyst Funds Management first reported a position in AMRX in Q1 2024 and has held it in 6 quarters since. The position peaked at $313K in Q2 2025. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Catalyst Funds Management held 16,900 shares of Amneal Pharmaceuticals worth $293K as of Q2 2026.
  • Catalyst Funds Management sold 3,500 Amneal Pharmaceuticals shares in Q2 2026, an estimated $48K.
  • Amneal Pharmaceuticals made up 0.02% of Catalyst Funds Management's portfolio in Q2 2026, its #501 holding.
  • Catalyst Funds Management first reported a position in Amneal Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
  • Catalyst Funds Management's Amneal Pharmaceuticals position peaked at $313K in Q2 2025.
  • 306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.